APAC Digital PCR and qPCR Market

APAC Digital PCR and qPCR Market Size (2024 to 2029)

The size of the Asia Pacific Digital PCR and qPCR Market was worth USD 873.03 million in 2024 and is expected to grow at a rate of 8.9% to reach USD 1337.11 billion in 2029.

Over the past decade, demand has steadily increased in the APAC Digital PCR and qPCR market due to the increased use of genomic analysis techniques (microbiological identification and gene mutation detection) in the diagnosis of major infectious diseases (HIV, tuberculosis, malaria, hepatitis, staphylococci, etc.) and genetic disorders (such as cancer and syndromes). The increased global prevalence of target organisms, coupled with the effectiveness of qPCR and dPCR assays in diagnosing and estimating pathogenic microorganisms, has facilitated the use of clinical diagnostic tests (including qPCR and dPCR assays) and Asia-Pacific market growth. According to UNAIDS, about 36.9 million people worldwide are affected by HIV/AIDS as of 2017, with an average mortality of 900,000. Of these, 1.8 million new cases of HIV infection were reported in 2017 alone. In addition, in 2017, approximately 6.4 million new cases of TB were registered worldwide (WHO data, 2019). As of 2018, about 219 million patients worldwide have malaria, and 92% of cases were reported in WHO Africa alone.

The technical shortcomings of dPCR and qPCR and the high cost of advanced PCR equipment have limited the growth of digital PCR (dPCR) and real-time PCR (qPCR) in the Asia-Pacific market.

The typical PCR analysis with dPCR instruments involves various integrated technologies (PCR, microfluidics, and nanofabrication) to achieve the desired process results. These devices are small and have short cycle times. However, the development of such devices requires significant capital investment and extensive scientific validation at the nanometer level.

A key driver of APAC Digital PCR and qPCR market growth is the increasing incidence of infectious and genetic diseases worldwide. Also, advances in PCR technology and the continuous development of PCR-based research activities complement market growth. Besides, the transition from undeveloped areas and plant-based drugs to genomic-based drugs will support growth in the digital PCR (dPCR) and real-time PCR (qPCR) market.

This research report on the APAC digital PCR and the qPCR market has been segmented & sub-segmented into the following categories

APAC Digital PCR and qPCR Market Analysis By Product

• Consumables

• Reagents and Instruments

APAC Digital PCR and qPCR Market Analysis By Technology

• Quantitative PCR

• Digital PCR

APAC Digital PCR and qPCR Market Analysis By Application

• Tumors

• Blood Testing

• Pathogen Detection
• Research & Forensics

APAC Digital PCR and qPCR Market Analysis By End User

• Hospitals

• Research & Forensic Centers
• Pharmaceutical & Bio-Technological Firms
• Academic Institutions

APAC Digital PCR and qPCR Market Analysis By Country

• India

• China
• Japan
• South Korea
• Australia
• New Zealand
• Thailand
• Malaysia
• Vietnam
• Philippines
• Indonesia
• Singapore
• Rest of APAC

Regionally, the leading pharmaceutical companies' extensive research and development activities are supporting the business growth of digital PCR and qPCRs in the Asia Pacific region. In addition, the presence of healthcare providers, government plans for better molecular diagnostics in disease diagnosis, and continuous improvement in diagnostic reimbursement programs are expected to drive the regional market from 2019 to 2024. The emergence of automated PCR equipment, a high understanding of the latest medical technologies, increased purchasing power, and affordability could drive the Asia Pacific dPCR and qPCR markets. Also, the growing elderly population is anticipated to drive market growth in the region.

Furthermore, factors expected to drive the Asia-Pacific market include improved healthcare infrastructure, increased private and public investment in life sciences research, and technological advances in China and India. As a result, the region will witness the fastest compound annual growth rate of 11% during the forecast period. Increased use of PCR in disease diagnosis is also foreseen to drive market growth in the region, as R & D expenditures are rising due to significant economic development. Countries like China, Japan, India, and others are presumed to become potential markets with evolving medical diagnostic infrastructure and high healthcare spending.

KEY MARKET PLAYERS

A few of the prominent companies operating in the APAC Digital PCR and qPCR market profiled in this report are Thermo Fisher Scientific Inc., F Hoffman-La Roche Ltd., Bio-Rad Laboratories, Qiagen N.V., Taraka Bio Inc., Affymetrix Inc., Agilent Technologies Inc., Fluidigm Corporation, Danaher Corporation, and Becton & Dickson Company.